The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study
Abdellatif Tazi, Constance de Margerie, Jean Marc Naccache, Stéphanie Fry, Stéphane Dominique, Stéphane Jouneau, Gwenaël Lorillon, Emmanuelle Bugnet, Raphael Chiron, Benoit Wallaert, Dominique Valeyre, Sylvie Chevret, Abdellatif Tazi, Constance de Margerie, Jean Marc Naccache, Stéphanie Fry, Stéphane Dominique, Stéphane Jouneau, Gwenaël Lorillon, Emmanuelle Bugnet, Raphael Chiron, Benoit Wallaert, Dominique Valeyre, Sylvie Chevret
Abstract
Background: The natural history of pulmonary Langerhans cell histiocytosis (PLCH) has been unclear due to the absence of prospective studies. The rate of patients who experience an early progression of their disease is unknown. Additionally, conflicting effects of smoking cessation on the outcome of PLCH have been reported.
Methods: In this prospective, multicentre study, 58 consecutive patients with newly diagnosed PLCH were comprehensively evaluated over a two-year period. Our objectives were to estimate the incidence of early progression of the disease and to evaluate the impact of smoking status on lung function outcomes. Lung function deterioration was defined as a decrease of at least 15% in FEV1 and/or FVC and/or DLCO, compared with baseline values. At each visit, smoking status was recorded based on the patients' self-reports and urinary cotinine measurements that were blinded for the patients. The cumulative incidence of lung function outcomes over time was estimated using the non-parametric Kaplan-Meier method. Multivariate Cox models with time-dependent covariates were used to calculate the hazards ratios of the lung function deterioration associated with smoking status with adjustment for potential confounders.
Results: The cumulative incidence of lung function deterioration at 24 months was 38% (22% for FEV1 and DLCO, and 9% for FVC). In the multivariate analysis, smoking status and PaO2 at inclusion were the only factors associated with the risk of lung function deterioration. The patients' smoking statuses markedly changed over time. Only 20% of the patients quit using tobacco for the entire study period. Nevertheless, being a non-smoker was associated with a decreased risk of subsequent lung function deterioration, even after adjustment for baseline predictive factors. By serial lung computed tomography, the extent of cystic lesions increased in only 11% of patients.
Conclusions: Serial lung function evaluation on a three- to six-month basis is essential for the follow-up of patients with recently diagnosed PLCH to identify those who experience an early progression of their disease. These patients are highly addicted to tobacco, and robust efforts should be undertaken to include them in smoking cessation programs.
Trial registration: ClinicalTrials.gov: No: NCT01225601 .
Figures
References
- Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis. 2012;7:16. doi: 10.1186/1750-1172-7-16.
- Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2006;27:1272–85. doi: 10.1183/09031936.06.00024004.
- Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans’-cell histiocytosis. N Engl J Med. 2000;342:1969–78. doi: 10.1056/NEJM200006293422607.
- Dauriat G, Mal H, Thabut G, Mornex JF, Bertocchi M, Tronc F, et al. Lung transplantation for pulmonary Langerhans’ cell histiocytosis: a multicenter analysis. Transplant. 2006;81:746–50. doi: 10.1097/.
- Tazi A, Marc K, Dominique S, de Bazelaire C, Crestani B, Chinet T, et al. Serial computed tomography and lung function testing in pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2012;40:905–12. doi: 10.1183/09031936.00210711.
- Bernstrand C, Cederlund K, Sandstedt B, Ahström L, Lundell M, Dahlquist G, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol. 2001;36:459–68. doi: 10.1002/mpo.1110.
- Mogulkoc N, Veral A, Bishop PW, Bayindir U, Pickering CA, Egan JJ. Pulmonary Langerhans’ cell histiocytosis: radiologic resolution following smoking cessation. Chest. 1999;115:1452–5. doi: 10.1378/chest.115.5.1452.
- Negrin-Dastis S, Butenda D, Dorzee J, Fastrez J, d’Odémont JP. Complete disappearance of lung abnormalities on high-resolution computed tomography: a case of histiocytosis X. Can Respir J. 2007;14:235–7.
- Schönfeld N, Dirks K, Costabel U, Loddenkemper R. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten. A prospective clinical multicentre study on adult pulmonary Langerhans’ cell histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:132–8.
- Tazi A, Montcelly L, Bergeron A, Valeyre D, Battesti JP, Hance AJ. Relapsing nodular lesions in the course of adult pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med. 1998;157:2007–10. doi: 10.1164/ajrccm.157.6.9709026.
- Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med. 2002;346:484–90. doi: 10.1056/NEJMoa012087.
- Westerlaan HE, van der Valk PD. Clinical and radiological evolution in patients with pulmonary Langerhans’ cell histiocytosis. Neth J Med. 2002;60:320–6.
- Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996;18:188–204. doi: 10.1093/oxfordjournals.epirev.a017925.
- Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25–31. doi: 10.1016/S0954-6111(06)80166-6.
- Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT) Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219–63. doi: 10.1183/09031936.00139009.
- Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis. Proc Am Thorac Soc. 2006;3:299–306. doi: 10.1513/pats.200512-135TK.
- Vassallo R, Jensen EA, Colby TV, Ryu JH, Douglas WW, Hartman TE, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest. 2003;124:1199–205. doi: 10.1378/chest.124.4.1199.
- Basset F, Corrin B, Spencer H, Lacronique J, Roth C, Soler P, et al. Pulmonary histiocytosis X. Am Rev Respir Dis. 1978;118:811–20.
- Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology. 1997;204:497–502. doi: 10.1148/radiology.204.2.9240543.
- Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. ECLIPSE Investigators: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92. doi: 10.1056/NEJMoa1105482.
- Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X). Groupe d’etude en pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J. 1996;9:2002–6. doi: 10.1183/09031936.96.09102002.
- Lynch JP, 3rd, Weigt SS, DerHovanessian A, Fishbein MC, Gutierrez A, Belperio JA. Obliterative (constrictive) bronchiolitis. Semin Respir Crit Care Med. 2012;33:509–32. doi: 10.1055/s-0032-1325161.
- Fartoukh M, Humbert M, Capron F, Maître S, Parent F, Le Gall C, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161:216–23. doi: 10.1164/ajrccm.161.1.9807024.
- Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest. 1997;111:1142–4. doi: 10.1378/chest.111.4.1142.
- Le Pavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest. 2012;142:1150–7. doi: 10.1378/chest.11-2490.
Source: PubMed